Join ACC's Prevention of Cardiovascular Disease Member Section this Wednesday, April 9 at 1 p.m. ET for a recap of ACC.25 prevention content and its influence on clinical practice. The webinar will ...

The ALIGN-AR trial contributes to the literature by demonstrating high technical success, a reassuring safety profile, and favorable clinical outcomes in high-risk patients with aortic regurgitation ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

In sharp contrast to earlier studies, patients with severe triple-vessel heart disease fared equally well whether they underwent open-heart bypass surgery (CABG) or a less invasive procedure called ...

Coronary atherosclerotic phenotypes, including total plaque volume (TPV), noncalcified plaque (NCP), calcified plaque (CP) and percentage atheroma volume (PAV), assessed by artificial ...

In patients experiencing excessive bleeding during cardiac surgery, a concentrated blood product containing proteins that help the blood clot was significantly more effective and caused fewer adverse ...

"Refocusing and reframing the definition and discussion of coronary artery disease (CAD) from late-stage ischemia and acute coronary events to early detection of coronary artery atheroma and ...

A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor’s antiplatelet effects in patients undergoing urgent surgery or experiencing major ...

The Advance-HTN trial showed that lorundrostat effectively lowered 24-hour SBP at 12 weeks among patients with uncontrolled and treatment-resistant hypertension vs. placebo. Participants at 103 U.S.

Extended anticoagulant therapy with a reduced-dose of apixaban was noninferior to extended therapy with a full-dose of apixaban in preventing recurrent venous thromboembolism (VTE) in patients with ...

Patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke at five years, according to research presented during ...

Implantation of an intra-aortic balloon pump (IABP) did not improve 60-day survival or bridge to heart replacement (HRT) therapies in patients with heart failure-cardiogenic shock (HF-CS) compared to ...